Selected research
Market Structure
Global Hemoderivative Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Hemoderivative market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Hemoderivative is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hemoderivative is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hemoderivative is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Hemoderivative is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Hemoderivative include CSL, Grifols, Kedrion, LFB Group, Octapharma, CBPO, Boya Bio, Hualan Bio and Shanghai RAAS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Hemoderivative market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hemoderivative and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hemoderivative sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hemoderivative market size, projected growth trends, production technologies, key applications, and end-use industries.
Hemoderivative Segment by Company
CSL
Grifols
Kedrion
LFB Group
Octapharma
CBPO
Boya Bio
Hualan Bio
Shanghai RAAS
Shuanglin Bio
Tiantan Bio
Weiguang Bio
Takeda
Yuanda Shuyang
Hemoderivative Segment by Type
Coagulation Factors
Immunoglobulins
Albumin
Others
Hemoderivative Segment by Application
Therapeutics
Excipient
Other
Hemoderivative Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemoderivative market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemoderivative and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemoderivative.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hemoderivative market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemoderivative manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hemoderivative in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hemoderivative in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Coagulation Factors
- Immunoglobulins
- Albumin
- Others
Applications
- Therapeutics
- Excipient
- Other
Companies covered
- CSL
- Grifols
- Kedrion
- LFB Group
- Octapharma
- CBPO
- Boya Bio
- Hualan Bio
- Shanghai RAAS
- Shuanglin Bio
- Tiantan Bio
- Weiguang Bio
- Takeda
- Yuanda Shuyang
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hemoderivative Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hemoderivative Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hemoderivative Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hemoderivative Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hemoderivative Market Dynamics
- 2.1 Hemoderivative Industry Trends
- 2.2 Hemoderivative Industry Drivers
- 2.3 Hemoderivative Industry Opportunities and Challenges
- 2.4 Hemoderivative Industry Restraints
3 Hemoderivative Market by Manufacturers
- 3.1 Global Hemoderivative Revenue by Manufacturers (2021-2026)
- 3.2 Global Hemoderivative Sales by Manufacturers (2021-2026)
- 3.3 Global Hemoderivative Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hemoderivative Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hemoderivative Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hemoderivative Manufacturers, Product Type & Application
- 3.7 Global Hemoderivative Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hemoderivative Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hemoderivative Players Market Share by Revenue in 2025
- 3.8.3 2025 Hemoderivative Tier 1, Tier 2, and Tier 3
4 Hemoderivative Market by Type
- 4.1 Hemoderivative Type Introduction
- 4.1.1 Coagulation Factors
- 4.1.2 Immunoglobulins
- 4.1.3 Albumin
- 4.1.4 Others
- 4.2 Global Hemoderivative Sales by Type
- 4.2.1 Global Hemoderivative Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hemoderivative Sales by Type (2021-2032)
- 4.2.3 Global Hemoderivative Sales Market Share by Type (2021-2032)
- 4.3 Global Hemoderivative Revenue by Type
- 4.3.1 Global Hemoderivative Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hemoderivative Revenue by Type (2021-2032)
- 4.3.3 Global Hemoderivative Revenue Market Share by Type (2021-2032)
5 Hemoderivative Market by Application
- 5.1 Hemoderivative Application Introduction
- 5.1.1 Therapeutics
- 5.1.2 Excipient
- 5.1.3 Other
- 5.2 Global Hemoderivative Sales by Application
- 5.2.1 Global Hemoderivative Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hemoderivative Sales by Application (2021-2032)
- 5.2.3 Global Hemoderivative Sales Market Share by Application (2021-2032)
- 5.3 Global Hemoderivative Revenue by Application
- 5.3.1 Global Hemoderivative Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hemoderivative Revenue by Application (2021-2032)
- 5.3.3 Global Hemoderivative Revenue Market Share by Application (2021-2032)
6 Global Hemoderivative Sales by Region
- 6.1 Global Hemoderivative Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hemoderivative Sales by Region (2021-2032)
- 6.2.1 Global Hemoderivative Sales by Region (2021-2026)
- 6.2.2 Global Hemoderivative Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hemoderivative Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hemoderivative Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hemoderivative Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hemoderivative Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hemoderivative Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hemoderivative Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hemoderivative Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hemoderivative Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hemoderivative Revenue by Region
- 7.1 Global Hemoderivative Revenue by Region
- 7.1.1 Global Hemoderivative Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hemoderivative Revenue by Region (2021-2026)
- 7.1.3 Global Hemoderivative Revenue by Region (2027-2032)
- 7.1.4 Global Hemoderivative Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hemoderivative Revenue (2021-2032)
- 7.2.2 North America Hemoderivative Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hemoderivative Revenue (2021-2032)
- 7.3.2 Europe Hemoderivative Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hemoderivative Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hemoderivative Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hemoderivative Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hemoderivative Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSL
- 8.1.1 CSL Company Information
- 8.1.2 CSL Business Overview
- 8.1.3 CSL Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSL Hemoderivative Product Portfolio
- 8.1.5 CSL Recent Developments
- 8.2 Grifols
- 8.2.1 Grifols Company Information
- 8.2.2 Grifols Business Overview
- 8.2.3 Grifols Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Grifols Hemoderivative Product Portfolio
- 8.2.5 Grifols Recent Developments
- 8.3 Kedrion
- 8.3.1 Kedrion Company Information
- 8.3.2 Kedrion Business Overview
- 8.3.3 Kedrion Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Kedrion Hemoderivative Product Portfolio
- 8.3.5 Kedrion Recent Developments
- 8.4 LFB Group
- 8.4.1 LFB Group Company Information
- 8.4.2 LFB Group Business Overview
- 8.4.3 LFB Group Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 LFB Group Hemoderivative Product Portfolio
- 8.4.5 LFB Group Recent Developments
- 8.5 Octapharma
- 8.5.1 Octapharma Company Information
- 8.5.2 Octapharma Business Overview
- 8.5.3 Octapharma Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Octapharma Hemoderivative Product Portfolio
- 8.5.5 Octapharma Recent Developments
- 8.6 CBPO
- 8.6.1 CBPO Company Information
- 8.6.2 CBPO Business Overview
- 8.6.3 CBPO Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 CBPO Hemoderivative Product Portfolio
- 8.6.5 CBPO Recent Developments
- 8.7 Boya Bio
- 8.7.1 Boya Bio Company Information
- 8.7.2 Boya Bio Business Overview
- 8.7.3 Boya Bio Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Boya Bio Hemoderivative Product Portfolio
- 8.7.5 Boya Bio Recent Developments
- 8.8 Hualan Bio
- 8.8.1 Hualan Bio Company Information
- 8.8.2 Hualan Bio Business Overview
- 8.8.3 Hualan Bio Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Hualan Bio Hemoderivative Product Portfolio
- 8.8.5 Hualan Bio Recent Developments
- 8.9 Shanghai RAAS
- 8.9.1 Shanghai RAAS Company Information
- 8.9.2 Shanghai RAAS Business Overview
- 8.9.3 Shanghai RAAS Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Shanghai RAAS Hemoderivative Product Portfolio
- 8.9.5 Shanghai RAAS Recent Developments
- 8.10 Shuanglin Bio
- 8.10.1 Shuanglin Bio Company Information
- 8.10.2 Shuanglin Bio Business Overview
- 8.10.3 Shuanglin Bio Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Shuanglin Bio Hemoderivative Product Portfolio
- 8.10.5 Shuanglin Bio Recent Developments
- 8.11 Tiantan Bio
- 8.11.1 Tiantan Bio Company Information
- 8.11.2 Tiantan Bio Business Overview
- 8.11.3 Tiantan Bio Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Tiantan Bio Hemoderivative Product Portfolio
- 8.11.5 Tiantan Bio Recent Developments
- 8.12 Weiguang Bio
- 8.12.1 Weiguang Bio Company Information
- 8.12.2 Weiguang Bio Business Overview
- 8.12.3 Weiguang Bio Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Weiguang Bio Hemoderivative Product Portfolio
- 8.12.5 Weiguang Bio Recent Developments
- 8.13 Takeda
- 8.13.1 Takeda Company Information
- 8.13.2 Takeda Business Overview
- 8.13.3 Takeda Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Takeda Hemoderivative Product Portfolio
- 8.13.5 Takeda Recent Developments
- 8.14 Yuanda Shuyang
- 8.14.1 Yuanda Shuyang Company Information
- 8.14.2 Yuanda Shuyang Business Overview
- 8.14.3 Yuanda Shuyang Hemoderivative Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Yuanda Shuyang Hemoderivative Product Portfolio
- 8.14.5 Yuanda Shuyang Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hemoderivative Value Chain Analysis
- 9.1.1 Hemoderivative Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hemoderivative Production Mode & Process
- 9.2 Hemoderivative Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hemoderivative Distributors
- 9.2.3 Hemoderivative Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst